Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;7(1):9-14.
doi: 10.4161/19420862.2015.989042.

The therapeutic monoclonal antibody market

Dawn M Ecker  1 , Susan Dana Jones, Howard L Levine
Affiliations
Review

The therapeutic monoclonal antibody market

Dawn M Ecker et al. MAbs. 2015.

Abstract

Since the commercialization of the first therapeutic monoclonal antibody product in 1986, this class of biopharmaceutical products has grown significantly so that, as of November 10, 2014, forty-seven monoclonal antibody products have been approved in the US or Europe for the treatment of a variety of diseases, and many of these products have also been approved for other global markets. At the current approval rate of ∼ four new products per year, ∼ 70 monoclonal antibody products will be on the market by 2020, and combined world-wide sales will be nearly $125 billion.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Annual approvals of monoclonal antibody products.3,4 The number of monoclonal antibody products first approved for commercial sale in the US or Europe each year since 1982 is shown. The totals include all monoclonal antibody and antibody-related products. Products approved but subsequently removed from the market are denoted in blue; products currently marketed are denoted in green. 2014 total is as of November 10, 2014.
Figure 2.
Figure 2.
Sales of biopharmaceutical products by product type. Total annual sales of biopharmaceutical products are shown as a function of product type. Note that recombinant proteins produced by microbial fermentation include recombinant human insulin products which represent nearly 50% of the sales and >90% of the material produced in this category.
Figure 3.
Figure 3.
Annual sales of monoclonal antibody products. Annual sales of the top six selling monoclonal antibodies compared to the non-antibody recombinant proteins Avonex and Rebif for the period 2004 to 2013. Each monoclonal antibody product had 2013 sales of greater than $6.5 billion. Sales information was obtained from company annual reports and other publically available sources.
See this image and copyright information in PMC

References

    1. Bioprocess Technology Consultants [Internet] Woburn (MA): Bioprocess Technology Consultants, Inc. bioTRAK® database; 2014. [cited 2014 September 14]; [about 2 screens] Available from: http://www.bptc.com/pipeline-databases.php
    1. Pharmaceutical Research and Manufacturers of America Medicines in development: Biologics 2013 Report [Internet]. Washington, DC: Pharmaceutical Research and Manufacturers of America; 2013 Mar. [cited 2014 September 14] 87 p. Available from: http://www.phrma.org/sites/default/files/pdf/biologics2013.pdf
    1. Drugs@FDA [Internet] Silver Spring (MD): U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 1939- [cited 2014 September 14] Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
    1. European public assessment reports, human medicines [Internet] London: The European Medicines Agency. 1995. [cited 2014 September 14] Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar...
    1. Ecker DM, Ransohoff TC, Jones SD, Levine HL. The state of mammalian cell culture biomanufacturing. Woburn: (MA: ): BioProcess Technology Consultants, Inc; 2011 Dec 12; 150 p. Available from: http://www.bptc.com/ECommerce/Reports.

Substances